Intellia Therapeutics Inc. (NTLA)

$14.79

+0.49

(+3.43%)▲

Market is closed - opens 8 PM, 26 Nov 2024

Intellia Therapeutics Inc. Key Statistics

Market Capitalization
$1.4B
Revenue TTM
$43.1M
EBITDA
$-527.5M
Earnings Per Share (EPS)
$-5.45
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-52.23%

Intellia Therapeutics Inc. share price movements

  • $14.47
    $15.24
    $14.79
    downward going graph

    2.2%

    Downside

    Day's Volatility :5.09%

    Upside

    2.95%

    downward going graph
  • $12.82
    $34.87
    $14.79
    downward going graph

    13.32%

    Downside

    52 Weeks Volatility :63.23%

    Upside

    57.59%

    downward going graph

Intellia Therapeutics Inc. Returns

PeriodIntellia Therapeutics Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-37.28%
-6.4%
0.0%
6 Months
-34.9%
0.7%
0.0%
1 Year
-51.75%
10.9%
0.0%
3 Years
-86.93%
10.2%
-21.2%

Analyst Recommendation on Intellia Therapeutics Inc.

Buy
    79%Buy
    20%Hold
    0
    0%Sell
Based on 34 Wall street analysts offering stock ratings for Intellia Therapeutics Inc.(by analysts ranked 0 to 5 stars)
Based on 34 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
27
27
28
Hold
7
7
5
Sell
00
00
00

Analyst Forecast on Intellia Therapeutics Inc.

What analysts predicted

Upside of 304.19%

Current $14.79
Target $59.78

Insights on Intellia Therapeutics Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 6.95M → 9.11M (in $), with an average increase of 23.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -146.97M → -135.71M (in $), with an average increase of 8.3% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 54.1% return, outperforming this stock by 106.4%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 33.1% return, outperforming this stock by 120.0%

Intellia Therapeutics Inc. Financials in INR & Dollars

FY18Y/Y Change
Revenue
30.4M
↑ 16.53%
Net Income
-85.3M
↑ 26.35%
Net Profit Margin
-280.42%
↓ 21.8%
FY19Y/Y Change
Revenue
43.1M
↑ 41.63%
Net Income
-92.7M
↑ 8.62%
Net Profit Margin
-215.06%
↑ 65.36%
FY20Y/Y Change
Revenue
58.0M
↑ 34.55%
Net Income
-125.6M
↑ 35.46%
Net Profit Margin
-216.52%
↓ 1.46%
FY21Y/Y Change
Revenue
33.1M
↓ 43.01%
Net Income
-259.7M
↑ 106.83%
Net Profit Margin
-785.76%
↓ 569.24%
FY22Y/Y Change
Revenue
52.1M
↑ 57.69%
Net Income
-490.2M
↑ 88.75%
Net Profit Margin
-940.52%
↓ 154.76%
FY23Y/Y Change
Revenue
36.3M
↓ 30.4%
Net Income
-481.2M
↓ 1.84%
Net Profit Margin
-1.3K%
↓ 385.99%
Q2 FY23Q/Q Change
Revenue
13.6M
↑ 7.84%
Net Income
-123.7M
↑ 33.94%
Net Profit Margin
-909.82%
↓ 177.28%
Q3 FY23Q/Q Change
Revenue
12.0M
↓ 11.78%
Net Income
-122.2M
↓ 1.18%
Net Profit Margin
-1.0K%
↓ 109.39%
Q4 FY23Q/Q Change
Revenue
-1.9M
↓ 115.99%
Net Income
-132.2M
↑ 8.13%
Net Profit Margin
6.9K%
↑ 7913.37%
Q1 FY24Q/Q Change
Revenue
28.9M
↓ 1609.39%
Net Income
-107.4M
↓ 18.71%
Net Profit Margin
-371.3%
↓ 7265.46%
Q2 FY24Q/Q Change
Revenue
7.0M
↓ 75.96%
Net Income
-147.0M
↑ 36.8%
Net Profit Margin
-2.1K%
↓ 1741.32%
Q3 FY24Q/Q Change
Revenue
9.1M
↑ 30.96%
Net Income
-135.7M
↓ 7.66%
Net Profit Margin
-1.5K%
↑ 623.08%
FY18Y/Y Change
Total Assets
347.3M
↓ 7.69%
Total Liabilities
69.4M
↓ 8.25%
FY19Y/Y Change
Total Assets
334.3M
↓ 3.75%
Total Liabilities
64.4M
↓ 7.2%
FY20Y/Y Change
Total Assets
676.3M
↑ 102.32%
Total Liabilities
149.3M
↑ 131.76%
FY21Y/Y Change
Total Assets
1.3B
↑ 91.4%
Total Liabilities
254.2M
↑ 70.33%
FY22Y/Y Change
Total Assets
1.5B
↑ 17.43%
Total Liabilities
284.5M
↑ 11.92%
FY23Y/Y Change
Total Assets
1.3B
↓ 14.42%
Total Liabilities
250.8M
↓ 11.85%
Q2 FY23Q/Q Change
Total Assets
1.3B
↓ 6.68%
Total Liabilities
218.4M
↓ 3.83%
Q3 FY23Q/Q Change
Total Assets
1.2B
↓ 6.04%
Total Liabilities
205.9M
↓ 5.69%
Q4 FY23Q/Q Change
Total Assets
1.3B
↑ 4.63%
Total Liabilities
250.8M
↑ 21.79%
Q1 FY24Q/Q Change
Total Assets
1.3B
↓ 3.18%
Total Liabilities
223.5M
↓ 10.91%
Q2 FY24Q/Q Change
Total Assets
1.2B
↓ 5.4%
Total Liabilities
220.5M
↓ 1.33%
Q3 FY24Q/Q Change
Total Assets
1.2B
↓ 1.53%
Total Liabilities
210.7M
↓ 4.42%
FY18Y/Y Change
Operating Cash Flow
-61.3M
↓ 6.16%
Investing Cash Flow
-260.8M
↑ 2484.3%
Financing Cash Flow
40.2M
↓ 71.87%
FY19Y/Y Change
Operating Cash Flow
-103.2M
↑ 68.54%
Investing Cash Flow
25.2M
↓ 109.65%
Financing Cash Flow
76.4M
↑ 90.05%
FY20Y/Y Change
Operating Cash Flow
-49.9M
↓ 51.65%
Investing Cash Flow
-214.5M
↓ 951.95%
Financing Cash Flow
371.8M
↑ 386.41%
FY21Y/Y Change
Operating Cash Flow
-225.0M
↑ 350.85%
Investing Cash Flow
-550.8M
↑ 156.79%
Financing Cash Flow
736.7M
↑ 98.15%
FY22Y/Y Change
Operating Cash Flow
-333.3M
↑ 48.11%
Investing Cash Flow
160.3M
↓ 129.11%
Financing Cash Flow
583.0M
↓ 20.87%
Q2 FY23Q/Q Change
Operating Cash Flow
-90.3M
↓ 17.38%
Investing Cash Flow
-34.5M
↓ 71.75%
Financing Cash Flow
2.5M
↑ 13.28%

Intellia Therapeutics Inc. Technicals Summary

Sell

Neutral

Buy

Intellia Therapeutics Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Intellia Therapeutics Inc. Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Intellia Therapeutics Inc.
Intellia Therapeutics Inc.
-9.49%
-34.9%
-51.75%
-86.93%
-11.22%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-19.29%
-22.98%
-6.09%
16.5%
106.01%
Biontech Se
Biontech Se
6.62%
28.33%
24.67%
-65.3%
465.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-12.52%
67.25%
57.65%
33.12%
110.8%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.08%
3.32%
31.85%
151.49%
110.78%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Intellia Therapeutics Inc.
Intellia Therapeutics Inc.
NA
NA
-0.1
-5.28
-0.52
-0.28
NA
9.46
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.25
18.25
1.1
44.91
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.04
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.18
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Intellia Therapeutics Inc.
Intellia Therapeutics Inc.
Buy
$1.4B
-11.22%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$81.1B
106.01%
18.25
33.61%
Biontech Se
Biontech Se
Buy
$27.1B
465.36%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$31.6B
110.8%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.1B
110.78%
32.84
-4.51%

Intellia Therapeutics Inc. Institutional Holdings

  • ARK Investment Management LLC

    11.39%

  • Vanguard Group Inc

    9.46%

  • BlackRock Inc

    9.43%

  • Deep Track Capital, LP

    4.86%

  • Morgan Stanley - Brokerage Accounts

    4.59%

  • State Street Corp

    4.29%

Corporate Announcements

  • Intellia Therapeutics Inc. Earnings

    Intellia Therapeutics Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information about Intellia Therapeutics Inc.

intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the

Organization
Intellia Therapeutics Inc.
Employees
526
CEO
Dr. John M. Leonard M.D.
Industry
Health Technology

FAQs